Product Dossier
REAPTAN
Product Dossier for REAPTAN (amlodipine, perindopril arginine, Servier Laboratories (Aust)). ARTG record, PBS listing, PBAC outcomes — compiled by…
- Sponsor: Servier Laboratories (Aust)
- Active ingredient: amlodipine, perindopril arginine
- Therapeutic area: Cardiology
- Related brand: NORVASC
- Related brand: CADIVAST
- Related brand: PREXUM
- Same area: ATOZET
- Same area: OPSUMIT
What it is
REAPTAN is a combination tablet containing perindopril arginine and amlodipine besilate. It is available in four strengths: 5 mg perindopril arginine with 5 mg amlodipine, 5 mg perindopril arginine with 10 mg amlodipine, 10 mg perindopril arginine with 5 mg amlodipine, and 10 mg perindopril arginine with 10 mg amlodipine.
Approved indications
The provided source documents do not contain information about the approved indications specific to REAPTAN as a combination product.
Dosing overview
The provided source documents do not contain dosing information for REAPTAN as a combination product.
Key safety warnings
The provided source documents do not contain safety warning information for REAPTAN.
Contraindications
The provided source documents do not contain contraindication information for REAPTAN.
PBS listing
The provided source documents do not contain Pharmaceutical Benefits Scheme listing information for REAPTAN.
Regulatory history
REAPTAN was first registered on the Australian Register of Therapeutic Goods on 4 November 2010. The registration includes four tablet strengths (5/5, 5/10, 10/5, and 10/10 mg combinations), all listed under licence category RE.